What if a cell therapy could work with the immune system rather than against it?
iPS cell therapies have enormous potential to cure cancer and many devastating diseases, but they’re hindered by the patient’s immune response.
Successful builder of multiple cell therapy companies including allogeneic T-cell, NK cell and γ𝛅T cell platforms
Pioneer of iPS-T cell research and Deputy Director at Center of iPS Cell Research and Application (CiRA) at Kyoto University
World-renowned leader in immune evasion technology and transplant surgeon at UCSF
…by slashing costs, cutting timelines, and providing treatments for millions of patients.
…by addressing tumor heterogeneity and enabling redosing for greater efficacy.
…and treating a wide range of intractable diseases, including autoimmune disorders.